Curis | CRIS - Selling And Administration Expenses


Curis reported $1.34M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 585K 84K Sep/2025
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
CSL USD 1.23B 498M Dec/2025
Curis USD 1.34M 3.45M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Exelixis USD 139.6M 16.58M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
Takeda JPY 292B 9.21B Mar/2026
TG Therapeutics USD 73.14M 22.42M Mar/2026
Verastem USD 24.44M 12.17M Dec/2025
Xoma USD 11M 2.54M Jun/2024